- Home
- AMBO vs RNAZ Comparison
AMBO vs RNAZ Comparison
Compare AMBO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- RNAZ
- Stock Information
- Founded
- AMBO 2000
- RNAZ 2016
- Country
- AMBO United States
- RNAZ United States
- Employees
- AMBO N/A
- RNAZ N/A
- Industry
- AMBO Other Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- RNAZ Health Care
- Exchange
- AMBO Nasdaq
- RNAZ Nasdaq
- Market Cap
- AMBO 7.2M
- RNAZ 7.2M
- IPO Year
- AMBO 2010
- RNAZ 2021
- Fundamental
- Price
- AMBO $2.65
- RNAZ $8.08
- Analyst Decision
- AMBO
- RNAZ Strong Buy
- Analyst Count
- AMBO 0
- RNAZ 1
- Target Price
- AMBO N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- AMBO 24.5K
- RNAZ 4.3M
- Earning Date
- AMBO 12-30-2024
- RNAZ 03-31-2025
- Dividend Yield
- AMBO N/A
- RNAZ N/A
- EPS Growth
- AMBO N/A
- RNAZ N/A
- EPS
- AMBO N/A
- RNAZ N/A
- Revenue
- AMBO $7,839,000.00
- RNAZ N/A
- Revenue This Year
- AMBO N/A
- RNAZ N/A
- Revenue Next Year
- AMBO N/A
- RNAZ N/A
- P/E Ratio
- AMBO N/A
- RNAZ N/A
- Revenue Growth
- AMBO N/A
- RNAZ N/A
- 52 Week Low
- AMBO $1.00
- RNAZ $2.66
- 52 Week High
- AMBO $5.55
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- AMBO 54.68
- RNAZ 48.31
- Support Level
- AMBO $2.34
- RNAZ $10.02
- Resistance Level
- AMBO $2.80
- RNAZ $11.30
- Average True Range (ATR)
- AMBO 0.31
- RNAZ 1.97
- MACD
- AMBO -0.02
- RNAZ -0.18
- Stochastic Oscillator
- AMBO 63.82
- RNAZ 26.75
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.